Cardiology Clinical Trials

We invite you to participate in the clinical trials of atrial fibrillation in Oklahoma City, OK. Hightower Clinical is conducting a cardiology clinical trial aiming to study and evaluate the safety and effectiveness of a device in patients with increased ischemic stroke risk.

If you’re between 18 years of age or older, have been diagnosed with paroxysmal, persistent, or permanent non-valvular AF, and meet specific criteria, you may be able to participate.

Your participation could potentially lead to significant advancements in treating atrial fibrillation. During your trial, you will receive expert study-related care from experienced physicians.

*All study procedures and study-related treatment, including the investigational drug, are free of cost, and insurance is not required to participate.*

We invite you to participate in the clinical trials of atrial fibrillation in Oklahoma City, OK. Hightower Clinical is conducting a cardiology clinical trial aiming to study and evaluate the safety, performance, and clinical benefits of the JETi device for treating acute/subacute thrombosis in the peripheral vasculature.

If you’re between 18 years of age or older, treated or are expected to be treated for acute/subacute thrombosis, and meet specific criteria, you may be able to participate.

During your trial, you will receive expert study-related care from experienced physicians. Participation is free of cost, and no insurance is required.

*All study procedures and study-related treatment, including the investigational drug, are free of cost, and insurance is not required to participate.*

Do you suffer from Cardiovascular Diseases and have elevated levels of cholesterol?

Cardiovascular diseases and their complications are among the leading causes of death in the United States and worldwide. To help reduce the burden of heart disease, Hightower is conducting Clinical Research in Cardiology.

We are currently enrolling volunteers in a Phase 3 Clinical Trial on an investigational medication for Atherosclerotic Cardiovascular Disease.

This study aims to observe whether the study drug could reduce 4-Point-Major Adverse Cardiovascular Events, non-fatal myocardial infarction (MI), non-fatal ischemic stroke, and urgent coronary revascularization.

*All study procedures and study-related treatment, including the investigational drug, are free of cost, and insurance is not required to participate.*